A US Drug Pricing Rebellion Looms, Analyst Says
Executive Summary
Wells Fargo analyst David Maris warned biopharma investors that the US drug market is on a long-term trajectory toward price controls, which he characterized as an under-appreciated risk for the sector, ahead of President Trump's speech on drug pricing.
You may also be interested in...
Who's Promised What: A Guide To Pharma Drug Pricing Pledges
Pharma companies have responded to mounting political pressure to lower drug prices by pledging to limit increases and even roll back the costs of certain drugs, but it's hard to keep track of who has promised what exactly. Here, Scrip provides a listing of pharma pricing pledges.
You Work In The Pharmaceutical Industry; Here's Why You Should Care About The Novartis Payments
There's a lot of finger-pointing in the industry when it comes to why pharma has a bad reputation. Maybe it's time everyone who works in pharmaceuticals takes responsibility for it.
You Work In The Pharmaceutical Industry; Here's Why You Should Care About The Novartis Payments
There's a lot of finger-pointing in the industry when it comes to why pharma has a bad reputation. Maybe it's time everyone who works in pharmaceuticals takes responsibility for it.